Smoke from wildfires can cause problems for those with respiratory and cardiac disease as well as the very young and the elderly. Smoke from forest and grass fires contains particles that can irritate eyes, throat and lungs. These can be bothersome to Continue reading Health Recommendations for Wildfire Smoke from National Jewish Health
• In honor of the program’s 25th anniversary, AbbVie is awarding three $25,000 scholarships, including a new award category – the Blogger’s Choice Award
• Cast a vote online or via text message, through October 13, 2017, to help determine this year’s Thriving Undergraduate and Continue reading AbbVie Announces 25th Annual Cystic Fibrosis Scholarship Program Including 2017 Thriving Student Scholarship Contest and Blogger’s Choice Award
Bitter taste receptors in the upper airway are a first line of defense against sinus infections, but their ability to kill harmful toxins and pathogens is blocked when the sweet taste receptors are also stimulated. While glucose and other sugars are known to Continue reading Blocking sweet taste receptors can help body fight off sinus infections
By: Jacob Greene
Cystic Fibrosis is an awkward disease. Whether it’s coughing attacks in the middle of tests, the infamous CF digestive issues (for professionalism’s sake I will leave it at that, but you know what I mean), or loud treatments in the morning and at night, there are many awkward aspects to cystic fibrosis. CF’s median life expectancy is no different. Continue reading We Can, Right? – Guest blog from USACFA Fall 2017 Scholarship Winner
NOVEMBER 5, 2017
STEP 1: REGISTER
To run for Team Boomer
STEP 2: INTERVIEW
with Team Boomer staffer Katie
STEP 3: RUN NEW YORK CITY! Continue reading Boomer Esiason Wants You… to Run the TCS NYC Marathon!
ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial
• Last patient received their final dose in the PQ-010-001 Phase 1b clinical trial of QR-010 in CF patients with the F508del mutation.
Top-line trial data are expected to be issued in a press release Continue reading Phase 1b Trial of QR-010
Published: Aug. 29, 2017
Michael Maiden, a Michigan State University College of Osteopathic Medicine student and doctoral candidate in the Department of Microbiology and Molecular Genetics, was Continue reading Fighting an old enemy in the battle against cystic fibrosis
Els van der Heijden, who has cystic fibrosis, was finding it ever harder to breathe as her lungs filled with thick, sticky mucus. Despite taking more than a dozen pills and inhalers a day, the 53-year-old had to stop Continue reading Lab-made “mini organs” helping doctors treat cystic fibrosis
Tezacaftor/Ivacaftor Gets Priority Review for Cystic Fibrosis
The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) of tezacaftor/ivacaftor (Vertex) for the treatment of patients ≥12yrs old with cystic fibrosis (CF) who have two copies of the F508del mutation or one F508del mutation and one residual function mutation.
The NDA submission was based on positive results from 2 global Phase 3 trials, which showed statistically significant improvements in lung function (percent predicted forced expiratory volume in one second, or ppFEV1) in patients treated with tezacaftor/ivacaftor.
The combination treatment consists of ivacaftor (marketed under the brand name Kalydeco), a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, and tezacaftor, a novel CFTR corrector. Tezacaftor is designed to address the processing defect of F508del-CFTR to enable it to reach the cell surface, where ivacaftor can further enhance the protein’s function.
The FDA has set a Prescription Drug User Fee Act (PDUFA) target date of February 28, 2018 to make a decision on the NDA.
For more information visit Vrtx.com.